1. Sakaguchi, S, Sakaguchi, N. Regulatory T cells in immunologic self-tolerance and autoimmune disease. International reviews of immunology 2005, 24(3-4), p. 211-226.
2. Kapp, J.A. Special regulatory T-cell review: Suppressors regulated but unsuppressed. Immunology 2008. 123(1), p. 28-32.
3. Pomie, C., Menager-Marcq, I., van Meerwijk, J.P. Murine CD8(+) regulatory T lymphocytes: The new era. Human immunology 2008, 69(11), p. 708-714.
4. Sakaguchi, S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nature immunology 2005, 6(4), p. 345-352.
5. Campbell, D.J., Ziegler, S.F. FOXP3 modifies the phenotypic and functional properties of regulatory T cells. Nature reviews 2007, 7(4), p. 305-310.
6. Vignali, D.A., Collison, L.W., Workman, C.J. How regulatory T cells work. Nature reviews 2008, 8(7), p. 523-532.
7. Curiel, T.J., Coukos, G., Zou, L. et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nature medicine 2004, 10(9), p. 942-949.
8. Wolf, A.M., Wolf, D., Steurer, M. et al. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin. Cancer Res. 2003, 9(2), p. 606-612.
9. Woo, E.Y., Chu, C.S., Goletz, T.J. et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer research 2001, 61(12), p. 4766-4772.
10. Schaefer, C., Kim, G.G., Albers, A. et al. Characteristics of CD4+CD25+ regulatory T cells in the peripheral circulation of patients with head and neck cancer. Br. J. Cancer 2005, 92(5), p. 913-920.
11. Strauss, L., Bergmann, C., Gooding, W. et al. The frequency and suppressor function of CD4+CD25highFoxp3+ T cells in the circulation of patients with squamous cell carcinoma of the head and neck. Clin. Cancer Res. 2007,13(21), p. 6301-6311.
12. Boucek, J., Mrkvan, T., Chovanec, M. et al. Regulatory T cells and their prognostic value for patients with squamous cell carcinoma of the head and neck. Journal of Cellular and Molecular Medicine. In press.
13. Groux, H., Cottrez, F. The complex role of interleukin-10 in autoimmunity. Journal of autoimmunity 2003, 20(4), p. 281-285.
14. Strauss, L., Bergmann, C., Whiteside, T.L. Functional and phenotypic characteristics of CD4+CD25highFoxp3+ Treg clones obtained from peripheral blood of patients with cancer. Int. J. Cancer. 2007, 121(11), p. 2473-2483.
15. Randolph, D.A., Fathman, C.G. Cd4+Cd25+ regulatory T cells and their therapeutic potential. Annual Review of Medicine 2006, 57, p. 381-402.
16. Sakaguchi, S., Sakaguchi, N., Asano, M. et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 1995, 155(3), p. 1151-1164.
17. Kronenberg, M., Rudensky, A. Regulation of immunity by self-reactive T cells. Nature 2005, 435(7042), p. 598-604.
18. Liu, W., Putnam, A.L., Xu-Yu, Z. et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J. Exp. Med. 2006, 203(7), p. 1701-1711.
19. Strauss, L., Bergmann, C., Szczepanski, M. et al. A unique subset of CD4+CD25 highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment. Clin. Cancer Res. 2007,13(15 Pt 1), p. 4345-4354.
20. Hilchey, S.P., De, A., Rimsza, L.M., Bankert, R.B., Bernstein, S.H. Follicular lymphoma intratumoral CD4+CD25+GITR+ regulatory T cells potently suppress CD3/CD28-costimulated autologous and allogeneic CD8+CD25- and CD4+CD25- T cells. J. Immunol. 2007, 178(7), p. 4051-4061.
21. Takahashi, T., Kuniyasu, Y., Toda, M. et al. Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int. Immunol. 1998, 10(12), p. 1969-1980.
22. Thornton, A.M., Shevach, E.M. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J. Exp. Med. 1998, 188(2), p. 287-296.
23. Jonuleit, H. Schmitt, E., Stassen, M. et al. Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood. J. Exp. Med. 2001, 193(11), p. 1285-1294.
24. Grossman, W.J., Verbsky, J.W., Tollefsen, B.L. et al. Differential expression of granzymes A and B in human cytotoxic lymphocyte subsets and T regulatory cells. Blood 2004, 104(9), p. 2840-2848.
25. Zhao, D.M., Thornton, A.M., DiPaolo, R.J., Shevach, E.M. Activated CD4+CD25+ T cells selectively kill B lymphocytes. Blood 2006, 107(10), p. 3925-3932.
26. Cao, X., Cai, S.F., Fehniger, T.A. et al. Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity 2007, 27(4), p. 635-646.
27. Bopp, T., Becker, C., Klein, M. et al. Cyclic adenosine monophosphate is a key component of regulatory T cell-mediated suppression. J. Exp. Med. 2007, 204(6), p. 1303-1310.
28. Deaglio, S., Dwyer, K.M., Gao, W. et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J. Exp. Med. 2007, 204(6), p. 1257-1265.
29. Fallarino, F., Grohmann, U., Hwang, K.W. et al. Modulation of tryptophan catabolism by regulatory T cells. Nature immunology 2003, 4(12), p. 1206-1212.
30. Mellor, A.L., Munn, D.H. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nature reviews 2004, 4(10), p. 762-774.
31. Liu, Y., Zhang, P., Li, J. et al. A critical function for TGF-beta signaling in the development of natural CD4+CD25+Foxp3+ regulatory T cells. Nature immunology 2008, 9(6), p. 632-640.
32. Verhasselt, V., Milcent, V., Cazareth, J. et al. Breast milk-mediated transfer of an antigen induces tolerance and protection from allergic asthma. Nature medicine 2008, 14(2), p. 170-175.
33. Whiteside, T.L. Anti-tumor vaccines in head and neck cancer: targeting immune responses to the tumor. Current cancer drug targets 2007, 7(7), p. 633-642.
34. Karcher, J., Dyckhoff, G., Beckhove, P. et al. Antitumor vaccination in patients with head and neck squamous cell carcinomas with autologous virus-modified tumor cells. Cancer research 2004, 64(21), p. 8057-8061.
35. Forastiere, A., Koch, W., Trotti, A., Sidransky, D. Head and neck cancer. NEJM 2001, 27, 345(26), p. 1890-1900.
36. Kim, C.H., Lee, J.S., Kang, S.O. et al. Serum hepatocyte growth factor as a marker of tumor activity in head and neck squamous cell carcinoma. Oral oncology 2007, 43(10), p. 1021-1025.
37. Brieger, J., Kastner, J., Gosepath, J., Mann, W.J. Evaluation of microsatellite amplifications at chromosomal locus 3q26 as surrogate marker for premalignant changes in mucosa surrounding head and neck squamous cell carcinoma. Cancer Genet. Cytogenet. 2006, 167(1), p. 26-31.
38. Kastner, J., Boucek, J., Betka, J. a kol. Časná kancerogeneze u spinocelulárního karcinomu hlavy a krku. Prakt. lék. 2008, 9, s. 501-505.
39. Plzak, J., Betka, J., Smetana, K. Jr. et al. Galectin-3 - an emerging prognostic indicator in advanced head and neck carcinoma. Eur. J. Cancer. 2004, 40(15), p. 2324-2330.
40. Cada, Z., Boucek, J., Dvorankova, B. et al. Nucleostemin expression in squamous cell carcinoma of the head and neck. Anticancer research 2007, 27(5A), p. 3279-3284.
41. Klozar, J., Kratochvil, V., Salakova, M. et al. HPV status and regional metastasis in the prognosis of oral and oropharyngeal cancer. Eur. Arch. Otorhinolaryngol. 2008, 265 Suppl 1, S75-82.
42. Smetana, K. Jr., Dvorankova, B., Lacina, L. et al. Human hair follicle and interfollicular keratinocyte reactivity to mouse HPV16-transformed cells: an in vitro study. Oncol. Rep. 2008, 20(1), p. 75-80.
43. Bergmann, C., Strauss, L., Wang, Y. et al. T regulatory type 1 cells in squamous cell carcinoma of the head and neck: mechanisms of suppression and expansion in advanced disease. Clin. Cancer Res. 2008, 14(12), p. 3706-3715.
44. Kuss, I., Hathaway, B., Ferris, R.L. et al. Decreased absolute counts of T lymphocyte subsets and their relation to disease in squamous cell carcinoma of the head and neck. Clin. Cancer Res. 2004, 10(11), p. 3755-3762.
45. Kuss, I., Hathaway, B., Ferris, R.L. et al. Imbalance in absolute counts of T lymphocyte subsets in patients with head and neck cancer and its relation to disease. Advances in oto-rhino-laryngology 2005, 62, p. 161-172.
46. Molling, J.W., Langius, J.A., Langendijk, J.A. et al. Low levels of circulating invariant natural killer T cells predict poor clinical outcome in patients with head and neck squamous cell carcinoma. J. Clin. Oncol. 2007, 25(7), p. 862-868.
47. Dong, H.P., Elstrand, M.B., Holth, A. et al. NK- and B-cell infiltration correlates with worse outcome in metastatic ovarian carcinoma. Am. J. Clin. Pathol. 2006, 125(3), p. 451-458.
48. Liyanage, U.K., Moore, T.T., Joo, H.G. et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J. Immunol. 2002, 169(5), p. 2756-2761.
49. Albers, A.E., Ferris, R.L., Kim, G.G. et al. Immune responses to p53 in patients with cancer: enrichment in tetramer+ p53 peptide-specific T cells and regulatory T cells at tumor sites. Cancer Immunol. Immunother. 2005, 54(11), p. 1072-1081.
50. Shevach, E.M. Regulatory/suppressor T cells in health and disease. Arthritis and rheumatism 2004, 50(9), p. 2721-2724.
51. Xu, L., Xu, W., Jiang, Z. et al. Depletion of CD4(+)CD25(high) regulatory T cells from tumor infiltrating lymphocytes predominantly induces Th1 type immune response in vivo which inhibits tumor growth in adoptive immunotherapy. Cancer Biol. Ther. 2009, 4, 8(1). (Epub ahead of print). Dostupné na http://www.ncbi.nlm.nih.gov/pubmed/19029829.
52. Curtin, J.F., Candolfi, M., Fakhouri, T.M. et al. Treg depletion inhibits efficacy of cancer immunotherapy: implications for clinical trials. PLoS ONE 2008, 3(4), e1983.
53. Shimizu, J., Yamazaki, S., Sakaguchi, S. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J. Immunol. 1999, 163(10), p. 5211-5218.
54. Antony, P.A., Restifo, N.P. CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2. J. Immunother. 2005, 28(2), p. 120-128.